TPWA
JAZZ icon

Twin Peaks Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27
Closed -$5.1K – 1228
2026
Q1 		$5.1K Buy
+27
New +$4.72K ﹤0.01% 1384
2025
Q3 		– Sell
-18
Closed -$2.04K – 1162
2025
Q2 		$2.04K Buy
+18
New +$1.96K ﹤0.01% 1618

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Twin Peaks Wealth Advisors's JAZZ Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 27 shares — an estimated $5.1K sold.

Twin Peaks Wealth Advisors first reported a position in JAZZ in Q2 2025 and held it in 2 quarters. The position peaked at $5.1K in Q1 2026. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 27 Jazz Pharmaceuticals shares in Q2 2026, an estimated $5.1K.
  • Twin Peaks Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Jazz Pharmaceuticals position peaked at $5.1K in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.